Insider Transactions Report

Ndu Adora, a director at ACADIA PHARMACEUTICALS INC, reported several transactions on May 29, 2026. Adora acquired 8,107 shares of Common Stock through a non-derivative transaction, increasing their post-transaction holdings to 32,908 shares. In derivative transactions, 8,107 Restricted Stock Units were disposed of, with the units vesting in full on the same date. Additionally, Adora was granted 16,004 Director Stock Options (Right to Buy) with an exercise price of $21.66, vesting quarterly over one year. Another grant of 9,311 Restricted Stock Units was also reported, vesting in full on the earlier of one year from the grant date or the next annual stockholders' meeting. All these derivative transactions were marked as acquired.